Director Karen H. Vousden filed a statement of changes in beneficial ownership with the U.S. Securities and Exchange Commission on September 15, 2026, disclosing the acquisition of a stock option covering 25,000 shares of Faeth Therapeutics, Inc. common stock.

Key Highlights

  • Reporting person: Karen H. Vousden, identified as a Director of Faeth Therapeutics, Inc. (NASDAQ:FTH)
  • Transaction date: September 11, 2026, with the filing submitted September 15, 2026
  • Option granted: A stock option (right to buy) covering 25,000 shares of common stock
  • Exercise price: $37.44 per share, acquired at a price of $0
  • Expiration date: September 10, 2036
  • Vesting schedule: 36 equal monthly installments over three years, fully vested on September 11, 2029, subject to continuous service
  • Post-transaction holdings: 25,000 derivative securities beneficially owned directly following the reported transaction

Karen H. Vousden Option Grant Details at Faeth Therapeutics

According to the filing, Karen H. Vousden, a Director at Faeth Therapeutics, Inc., acquired a stock option to purchase 25,000 shares of the company's common stock on September 11, 2026. The option carries an exercise price of $37.44 per share and was acquired at no cost to the reporting person. The option is listed as a derivative security under Table II of the filing and is held directly.

The filing states that the option vests and becomes exercisable "in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or September 11, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date." The option expires on September 10, 2036. Faeth Therapeutics, Inc. is a therapeutics company incorporated and headquartered in Austin, Texas, at 701 Tillery Street, and its shares trade on NASDAQ under the ticker FTH.

No non-derivative securities transactions were reported in Table I of the filing. The filing was signed by Josiah Craver as Attorney-in-Fact on September 15, 2026, and was filed by one reporting person. No amendment date was indicated, suggesting this is an original filing rather than a revision of a prior submission.

What Was Disclosed

The filing disclosed that Director Karen H. Vousden received a stock option covering 25,000 shares of Faeth Therapeutics common stock at an exercise price of $37.44, with a three-year monthly vesting schedule and a ten-year term expiring September 10, 2036.